<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144440</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-16-0096-CTIL</org_study_id>
    <nct_id>NCT03144440</nct_id>
  </id_info>
  <brief_title>Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel</brief_title>
  <official_title>Real World Experience of Chronic Hepatitis C Treatment in Israeli Patients With Advanced Liver Fibrosis With Fixed Dose Combination (FDC) Grazoprevir (100 mg)/Elbasvir (50mg) (Zepatier) ± Ribavirin: A Retrospective Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      1. To estimate the effectiveness of treatment with FDC of Zepatier with or without ribavirin&#xD;
      in Israeli patients with CHC and advanced fibrosis in real life setting.&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      1. To estimate the safety and tolerability of treatment with FDC of Zepatier with or without&#xD;
      ribavirin in real life setting in Israeli patients with CHC and advanced disease.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
      Effectiveness and tolerability of treatment with FDC of Zepatier with or without ribavirin in&#xD;
      Israeli patients with CHC and advanced fibrosis will be similar to that demonstrated in phase&#xD;
      3 clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following data will be collected:&#xD;
&#xD;
      Demographics information: age, gender, race, country of birth (COB). Data on liver and&#xD;
      virological characteristics: Hepatitis C virus(HCV) genotype, fibrosis stage (F0-4),&#xD;
      technology of fibrosis assessment (fibroscan, fibrotest, elastography, biopsy), , cirrhosis&#xD;
      (y/n), presence of portal hypertension: esophageal varices, ascites, hepatic encephalopathy,&#xD;
      history of decompensation, liver transplantation (y/n).&#xD;
&#xD;
      Previous anti-viral treatment: PR- Peg-Riba (relapse, partial/null responder, unknown&#xD;
      response), direct anti-viral agents (DDAs): Protease Inhibitors (PI) (Bocepravir,Telepravir,&#xD;
      Simepravir), Sofosbuvir (SOF), NS5A (Ledipasvir, Daclatasvir), NS5B.&#xD;
&#xD;
      Co-morbidities: BMI, Diabetes Mellitus, HIV-co infection, HBV-co infection, alcohol abuse,&#xD;
      CKD (Chronic kidney disease)/renal failure, cardiovascular disease, inherited blood&#xD;
      disorders, pre/post-transplant (liver/kidney) Concomitant medication (drug-drug&#xD;
      interactions): antiacids (Proton pump inhibitors,H2-blockers), statins,beta-blockers, oral&#xD;
      contraceptives, anti hypertensive, Anti retrovirals for HIV, etc.&#xD;
&#xD;
      Base line and end-of treatment parameters: White blood cells(WBC), Hemoglobin (HB),&#xD;
      Platelates (PLT), Alanine transferase (ALT), Aspartate transaminase (AST), Alpha phetoprotein&#xD;
      (ALP), Gamma glutamyl transferase (GGT), albumin, bilirubin, Protrombin time (PT)/INR, LDL-C,&#xD;
      IL28 (if available), Model for end stage liver disease (MELD) score, Child pugh (CPT)&#xD;
      score/class, viral load and virological response: HCV ribonucleic acid (RNA) at week 4 and 8&#xD;
      (if available), and sustained virological response (SVR) 12 and SVR24.&#xD;
&#xD;
      Data on virological breakthrough and relapse will be also collected and if possible to check&#xD;
      resistance associated variants (RAVs).&#xD;
&#xD;
      Data on treatment safety: any adverse event (AE), serious adverse event (SAE), AE which led&#xD;
      to early discontinuation of treatment; decompensation event (ascites, hepatic encephalopathy,&#xD;
      bleeding esophageal varices,) liver failure, liver transplantation and death.&#xD;
&#xD;
      Primary variable The proportion of patients achieving SVR12 (HCV RNA &lt;15 IU/mL at follow-up&#xD;
      week 12; 12 weeks after the last actual dose of the Zepatier).&#xD;
&#xD;
      The Full Analysis Set will include all patients who received ≥1 dose of Zepatier.&#xD;
&#xD;
      Secondary variables&#xD;
&#xD;
        -  Cirrhosis/Fibrosis stage (F3, F4). Cirrhosis defined by liver biopsy (Metavir F4);&#xD;
           transient elastography by Fibroscan tomography (TM) (&gt;12.5 kPa); or FibroTest® or&#xD;
           FibroSure® (&gt;0.75 with APRI &gt;2).&#xD;
&#xD;
        -  Previous HCV anti-viral treatment&#xD;
&#xD;
        -  Co-morbidities and concomitant medication&#xD;
&#xD;
        -  Laboratory abnormalities; baseline and end of treatment (EoT) parameters&#xD;
&#xD;
        -  Serious and non-serious adverse events occurring at any time during the treatment&#xD;
           period, and other adverse events up until 14 days after cessation of treatment, will be&#xD;
           collected and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virological response at week 12 (SVR12) [ Time Frame (for each patient): 12 weeks after the last dose of treatment ]</measure>
    <time_frame>12 weeks after the last dose of treatment</time_frame>
    <description>SVR12 is defined as hepatitis c virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification 12 weeks after the last dose of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Elbasvir/Grazoprevir treatment against HCV infection in real-life conditions is reflected as the number of patients with clinical and biological adverse events occurring during the treatment .</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse event from the time when the decision is made to initiate treatment with Elbasvir/Grazoprevir until after the last dose</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Hepatitis C</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Data collection from electronic patients' files from the different medical centers&#xD;
        participating in the study will be performed after completion of treatment and follow-up&#xD;
        period of up to 24 weeks post treatment (SVR).&#xD;
&#xD;
        Data will be collected every 4 months (3 times a year) and analyzed in one center (Carmel&#xD;
        Medical Center, Haifa, Israel).&#xD;
&#xD;
        Study interim report will be provided twice per year (middle and end of each year)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients that treated with Zepatier after SVR results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Eli Zuckerman</investigator_full_name>
    <investigator_title>Prof. Eli Zuckerman</investigator_title>
  </responsible_party>
  <keyword>ZEPATIER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

